PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
TI  - Dapagliflozin Does Not Impact Renal Function in Patients with Type 2 Diabetes
DP  - 2012 Dec 01
TA  - MD Conference Express
PG  - 21--21
VI  - 12
IP  - 16
4099  - http://mdc.sagepub.com/content/12/16/21.1.short
4100  - http://mdc.sagepub.com/content/12/16/21.1.full
AB  - Treatment with dapagliflozin (DAPA) is not associated with an increased risk of acute renal toxicity or long-term deterioration of renal function in patients with type 2 diabetes mellitus (T2DM) according to the results of a pooled analysis of 12 studies [NCT00263276; NCT00972244; NCT00528372; NCT00736879; NCT00528879; NCT00855166; NCT00357370; NCT00680745; NCT00683878; NCT00673231; NCT00643851; NCT00859898].